The U.S. House Select Committee on China launched an investigation into Bristol Myers Squibb, Merck, Pfizer, and AbbVie regarding clinical trials in China. This bipartisan inquiry focuses on trials conducted at Chinese military hospitals and within the Xinjiang region.
Lawmakers raised national security and ethical concerns regarding potential human rights abuses in these locations. The committee's letter to Bristol Myers Squibb’s CEO questions the company’s ability to ensure informed consent and protect intellectual property.
The investigation highlights risks that U.S. intellectual property could inadvertently support Chinese military capabilities. The committee requested detailed records on due diligence, data protection, and trial oversight by July 17.